| Name | Title | Contact Details |
|---|
Worldwide Clinical Research is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company`s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
There are three Otsuka pharmaceutical industry companies in the U.S.: Otsuka America Pharmaceutical, Inc. (OAPI) successfully commercializes Otsuka-discovered and in-licensed products in North America. Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) clinically develops and registers innovative healthcare products on a global basis. Otsuka Maryland Medicinal Laboratories, Inc. (OMML) is a basic research center investigating pharmacological compounds.
Fastrack Pharmaceuticals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Recro is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market. In addition to our experience in handling DEA controlled substances and developing and manufacturing modified release oral solid dosage forms, Recro has the expertise to deliver on our clients` pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 120,000 square feet, in Gainesville, Georgia.